Cargando…

Biophysical Characterization of Epigallocatechin-3-Gallate Effect on the Cardiac Sodium Channel Na(v)1.5

Epigallocatechin-3-Gallate (EGCG) has been extensively studied for its protective effect against cardiovascular disorders. This effect has been attributed to its action on multiple molecular pathways and transmembrane proteins, including the cardiac Na(v)1.5 channels, which are inhibited in a dose-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amarouch, Mohamed-Yassine, Kurt, Han, Delemotte, Lucie, Abriel, Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070937/ https://www.ncbi.nlm.nih.gov/pubmed/32085432 http://dx.doi.org/10.3390/molecules25040902

Ejemplares similares

Cellular hyper-excitability caused by mutations that alter the activation process of voltage-gated sodium channels
por: Amarouch, Mohamed-Yassine, et al.
Publicado: (2015)

Editorial: Inherited Arrhythmias of the Cardiac Sodium Channel Na(v)1.5
por: Amarouch, Mohamed-Yassine, et al.
Publicado: (2021)

Functional interaction between S1 and S4 segments in voltage-gated sodium channels revealed by human channelopathies
por: Amarouch, Mohamed-Yassine, et al.
Publicado: (2014)

In Silico Evaluation of the Potential Antiarrhythmic Effect of Epigallocatechin-3-Gallate on Cardiac Channelopathies
por: Boukhabza, Maroua, et al.
Publicado: (2016)

Electrophysiological properties of mouse and epitope-tagged human cardiac sodium channel Na (v)1.5 expressed in HEK293 cells
por: Reinhard, Katja, et al.
Publicado: (2013)

Functional cross-talk between phosphorylation and disease-causing mutations in the cardiac sodium channel Na(v)1.5
por: Galleano, Iacopo, et al.
Publicado: (2021)

Calmodulin binds to the N-terminal domain of the cardiac sodium channel Na(v)1.5
por: Wang, Zizun, et al.
Publicado: (2020)

Proteasome inhibitor (MG132) rescues Na(v)1.5 protein content and the cardiac sodium current in dystrophin-deficient mdx(5cv) mice
por: Rougier, Jean-Sébastien, et al.
Publicado: (2013)

Deletion of Trpm4 Alters the Function of the Na(v)1.5 Channel in Murine Cardiac Myocytes
por: Ozhathil, Lijo Cherian, et al.
Publicado: (2021)

Effects of Epigallocatechin-3-gallate (EGCG) on the bond strength of fiber posts to Sodium hypochlorite (NaOCl) treated intraradicular dentin
por: Yu, Hao-han, et al.
Publicado: (2017)

Skin Protective Effect of Epigallocatechin Gallate
por: Kim, Eunji, et al.
Publicado: (2018)

Modulation of Pore Opening of Eukaryotic Sodium Channels by π-Helices in S6
por: Choudhury, Koushik, et al.
Publicado: (2023)

Role of Epigallocatechin Gallate in Glucose, Lipid, and Protein Metabolism and L-Theanine in the Metabolism-Regulatory Effects of Epigallocatechin Gallate
por: Lin, Ling, et al.
Publicado: (2021)

Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na(+) Channels by Flecainide: Evidence from the Analysis of Disease-linked Mutations
por: Liu, Huajun, et al.
Publicado: (2002)

A Distinct Pool of Na(v)1.5 Channels at the Lateral Membrane of Murine Ventricular Cardiomyocytes
por: Rougier, Jean-Sébastien, et al.
Publicado: (2019)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Food-Grade Encapsulation Systems for (−)-Epigallocatechin Gallate
por: Shi, Meng, et al.
Publicado: (2018)

Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems
por: Granja, Andreia, et al.
Publicado: (2017)

Effect of Epigallocatechin Gallate on Viability of Kudoa septempunctata
por: Shin, Sang Phil, et al.
Publicado: (2020)

Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats
por: Hao, Jia, et al.
Publicado: (2007)

Characterization of the Synergistic Antioxidant Activity of Epigallocatechin Gallate (EGCG) and Kaempferol
por: Zhang, Qiang, et al.
Publicado: (2023)

Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
por: Xie, Qianjin, et al.
Publicado: (2021)

Proton-dependent inhibition of the cardiac sodium channel Na(v)1.5 by ranolazine
por: Sokolov, S., et al.
Publicado: (2013)

Life Cycle of the Cardiac Voltage-Gated Sodium Channel Na(V)1.5
por: Dong, Caijuan, et al.
Publicado: (2020)

Epigallocatechin-3-gallate and Epigallocatechin-3-O-(3-O-methyl)-gallate Enhance the Bonding Stability of an Etch-and-Rinse Adhesive to Dentin
por: Yu, Hao-Han, et al.
Publicado: (2017)

Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes
por: Laedermann, Cedric J., et al.
Publicado: (2015)

β1- and β3- voltage-gated sodium channel subunits modulate cell surface expression and glycosylation of Na(v)1.7 in HEK293 cells
por: Laedermann, Cédric J., et al.
Publicado: (2013)

Effect of Postnatal Epigallocatechin-Gallate Treatment on Cardiac Function in Mice Prenatally Exposed to Alcohol
por: Andreu-Fernández, Vicente, et al.
Publicado: (2023)

Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion
por: Chan, Chi-Ming, et al.
Publicado: (2010)

Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate
por: Patil, Pradeep R, et al.
Publicado: (2011)

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016)

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer
por: Wang, Liu-Xiang, et al.
Publicado: (2019)

The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate
por: Zeng, Jiajun, et al.
Publicado: (2018)

Melatonin and (−)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer
por: Zhang, Lingyun, et al.
Publicado: (2019)

Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate
por: Min, Kyoung-jin, et al.
Publicado: (2014)

Effects of Epigallocatechin-3-Gallate on Autophagic Lipolysis in Adipocytes
por: Kim, Sang-Nam, et al.
Publicado: (2017)

Preclinical Activities of Epigallocatechin Gallate in Signaling Pathways in Cancer
por: Sharifi-Rad, Mehdi, et al.
Publicado: (2020)

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
por: Cheong, Yucheol, et al.
Publicado: (2021)

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma
por: Li, Dongming, et al.
Publicado: (2023)

Zeolites with Divalent Ions as Carriers in the Delivery of Epigallocatechin Gallate
por: Sandomierski, Mariusz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8eisqbbgp3ae3evo2je2bl96lu